Modeling has shown that eliminating TB is not possible without addressing LTBI. (9) Comorbidities associated with TB include cancer, diabetes mellitus, and HIV. People with these medical conditions and compromised immune systems are more likely to develop active TB disease and to have worse outcomes from TB. (10) Forms of active TB that do not show drug resistance are classified as drug-susceptible TB (referred to in this section as DS–TB ). Drug-resistant TB (referred to in this section as DR–TB ) is a rising threat to the public health of the United States. DR–TB that exhibits resistance to two or more first-line drugs is referred to as multi-drug resistant TB (referred to in this section as MDR–TB ). MDR–TB that also is resistant to at least one injectable second-line medication and at least one fluoroquinolone is classified as extensively drug-resistant TB (referred to in this section as XDR–TB ). (11) Approximately 97 people in the United States were diagnosed with MDR–TB in 2018. One person was diagnosed with XDR–TB in the same year. (12) In the United States, $480 million was spent in 2018 to treat TB